What are the recommended surveillance and management strategies for Beckwith‑Wiedemann syndrome?

Beckwith-Wiedemann Syndrome: Surveillance and Management

Tumor Surveillance Protocol

All children with Beckwith-Wiedemann syndrome require standardized tumor surveillance with renal ultrasounds every 3 months from birth through age 7 years for Wilms tumor detection, and abdominal ultrasound with alpha-fetoprotein measurements every 3 months from birth through age 4 years for hepatoblastoma screening. 1, 2

Wilms Tumor Surveillance

• Perform renal ultrasounds (including adrenal glands) every 3 months starting at birth or diagnosis through the 7th birthday 1, 2
• This 3-month interval is critical because screening spaced beyond 4 months increases risk of interval tumor development 1
• 93% of Wilms tumors in BWS occur before age 8 years, with mean age at diagnosis of 24 months 1
• The screening frequency remains constant regardless of patient age, as tumor growth rate does not vary with age 1

Hepatoblastoma Surveillance

• Perform full abdominal ultrasound with serum alpha-fetoprotein (AFP) measurements every 3 months from birth through the 4th birthday 1, 2
• Most hepatoblastomas occur within the first year of life, with the oldest reported case at 30 months 1
• After the 4th birthday, transition to renal-only ultrasound every 3 months until the 7th birthday 1
• AFP screening is highly sensitive for hepatoblastoma detection 1

Neuroblastoma Surveillance (Molecular Subtype-Specific)

• For patients with CDKN1C mutations specifically, add neuroblastoma screening with urine catecholamines and chest radiographs 2, 3
• This represents 2.8% of CDKN1C mutation carriers who develop neuroblastoma 4

Clinical Features and Diagnosis

Cardinal Features

• Pre- and postnatal constitutional and organ overgrowth 1, 5
• Macroglossia (enlarged tongue) 5, 6
• Omphalocele or umbilical hernia 1, 5
• Facial nevus flammeus 1
• Hemihyperplasia (lateralized overgrowth) 5, 6
• Neonatal hypoglycemia 5, 6

Molecular Basis

• BWS is caused by dysregulation of imprinted growth genes on chromosome 11p15 2, 5
• Multiple molecular subtypes exist with different tumor risks 2, 4
• Tissue mosaicism can occur, making genetic testing challenging—a negative test does not exclude BWS 5

Tumor Risk by Molecular Subtype

High-Risk Subtypes

• IC1 (H19/IGF2:IG-DMR) gain of methylation: 28% overall tumor risk, predominantly Wilms tumor (24%) 2, 4
• Paternal uniparental disomy (pUPD): 16% overall tumor risk, with 7.9% Wilms tumor and 3.5% hepatoblastoma 4

Lower-Risk Subtypes

• IC2 (KCNQ1OT1:TSS-DMR) loss of methylation: 2.6% overall tumor risk, primarily hepatoblastoma (0.7%) 4
• CDKN1C mutations: 6.9% overall tumor risk, including 2.8% neuroblastoma 4
• No molecular defect detectable: 6.7% overall tumor risk 4

Important Caveat

Despite these molecular subtype-specific risks, current North American guidelines recommend uniform surveillance for all BWS patients regardless of molecular subtype. 1 This differs from some European centers that have implemented differentiated screening protocols based on molecular etiology 1. The uniform approach reflects the North American practice environment and provides a broad framework prioritizing early detection when minimally invasive screening significantly improves outcomes 1.

Multidisciplinary Management

Specialist Involvement

• Patients should be evaluated and monitored by cancer predisposition specialists (geneticists or pediatric oncologists) 1
• Physical examination by a specialist twice yearly is recommended 1
• These visits should include ongoing education about tumor manifestations, reinforcing screening rationale and compliance, and monitoring other syndrome-specific features 1

Genetic Counseling

• Genetic counseling is essential due to complex inheritance patterns and variable familial recurrence risks 2, 6
• Molecular subtype identification helps predict familial recurrence risks and tumor types 5, 6

Surgical Management

• Abdominal wall defects (omphalocele or umbilical hernia) require surgical repair 2
• Macroglossia may require tongue reduction surgery, with timing considerations balancing obstructive sleep apnea relief against perioperative complication risks 7
• Patients with pUPD have higher rates of reoperation for macroglossia 7

Critical Pitfalls to Avoid

• Do not discontinue Wilms tumor surveillance at age 4 years—continue through age 7 years as 93% of tumors occur before age 8 1
• Do not rely solely on clinical features for diagnosis—molecular testing is essential as 16% of Wilms tumor patients have at least one BWS feature even without classic presentation 1
• Do not assume negative genetic testing excludes BWS—tissue mosaicism can cause false negatives, and additional tissue samples or alternative testing methods may be needed 5
• Do not use fine-needle aspiration for suspected tumors—multiple core biopsies or surgical resection are required for adequate tissue diagnosis 3
• Do not forget hepatoblastoma screening—BWS has 2,280 times increased relative risk compared to the general population 1